Parabolan 100 - Ice Pharmaceuticals

First studied in 1967, trenbolone hexahydrobenzylcarbonate was part of a research push into long-acting anabolic esters. It was later developed into a therapeutic product by Negma, sold as Parabolan, and became widely used in France for patients with malnutrition and osteoporosis. Distinguished by its slow-release profile, Parabolan required fewer injections and had no aromatizing effects. Though praised for its performance, it was withdrawn from the market in 1997, and only rarely reappeared in limited or underground form thereafter.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Parabolan 100 by Ice Pharmaceuticals, consult with your doctor or healthcare professional.